Conference Coverage

When to transition heart failure patient to alternative loop diuretic


 

REPORTING FROM INTERNAL MEDICINE 2019

– While many internists might think a switch to spironolactone would be warranted for a heart failure patient with inadequate response to oral furosemide (Lasix), transitioning to an alternative loop diuretic may be the preferable approach, a cardiologist said at the annual meeting of the American College of Physicians.

Paul McKie, MD, MPH, a cardiologist and internist with Mayo Clinic, Rochester, Minn. Andrew D. Bowser/MDedge News

Dr. Paul McKie

“Lasix is associated with very high variability in terms of absorption, so torsemide and bumetanide should be considered in patients who have a poor response,” said Paul McKie, MD, MPH, a cardiologist and internist with Mayo Clinic, Rochester, Minn., in a session at the meeting.

When polled, only 22% of attendees at the session picked “transition to torsemide” as the best approach for restoring fluid balance with the lowest adverse potential in a 74-year-old woman with nonischemic cardiomyopathy on furosemide 80 mg twice daily who has been hospitalized for fluid overload three times in the year.

The majority of attendees (41%) said they would have added spironolactone. Dr. McKie disagreed with this approach. Instead, Dr. McKie said he would have transitioned this person to an alternative loop diuretic.

“I think spironolactone is a great medication in heart failure with reduced ejection fraction, but the doses we typically use are generally suboptimal to achieve diuresis,” he added.

The rationale for considering an alternative loop diuretic in this patient hinges on bioavailability, which is “highly variable” for oral furosemide, at 10%-100%, while by contrast, torsemide and bumetanide have a very consistent bioavailability of 80%-100%, according to Dr. McKie.

“For this reason, I think about using torsemide or bumetanide in patients who are not responding to oral Lasix,” he said.

Dr. McKie described an algorithm that he and his colleagues use in clinic to intensify outpatient therapy for patients not achieving diuresis.

The first step is to ensure adherence and ask patients whether they are following sodium and fluid restriction: “I always ask about that first,” he said. “I tell patients, ‘You can out-eat and out-drink any diuretic regimen.’ ”

The next step is to double the dose of the loop diuretic and, sometimes, triple the dose if the double dose is not effective.

“If they’re diuresing but it’s just not adequate, then I’ll move to twice-daily dosing,” he said. “A practical tip is I tell patients to take their first dose as soon as they wake up and the second dose around 1:00 PM so that they’re not urinating all night.”

If twice-daily dosing doesn’t help, then that’s the point where an alternative loop diuretic would be warranted, according to Dr. McKie’s algorithm.

“Then I add a thiazide like metolazone, but I only do that after I’ve increased the dose of the loop diuretic,” he added.

If all else fails, then outpatient IV diuretics can be considered, according to the algorithmic approach.

Dr. McKie reported no relevant disclosures.

Recommended Reading

Dapagliflozin’s cardiovascular benefits bloom in T2D with prior MI
Clinician Reviews
New data further suggest that stress does a number on the CV system
Clinician Reviews
Coughing Won’t Pay the Bills
Clinician Reviews
Low LDL cholesterol may increase women’s risk of hemorrhagic stroke
Clinician Reviews
PIONEER-HF Extension: Don’t stall starting sacubitril/valsartan
Clinician Reviews
Canagliflozin lowers kidney failure risk in T2D: CREDENCE
Clinician Reviews
Poor response to statins hikes risk of cardiovascular events
Clinician Reviews
Plant-based diet lowers risk of heart failure
Clinician Reviews
Dr. Joseph Vassalotti: Cancer risk minimal with ARBs
Clinician Reviews
Dr. Douglas Paauw gives updates on antihypertensives, statins, SGLT2 inhibitors
Clinician Reviews